| Disease Domain | Count | 
|---|---|
| Neoplasms | 2 | 
| Top 5 Drug Type | Count | 
|---|---|
| Trispecific killer cell engager (TriKE) | 2 | 
| Top 5 Target | Count | 
|---|---|
| CD16a x IL15R x TEM8 | 1 | 
| ADAM17 x CD276 x IL-15Rα | 1 | 
Target  | 
Mechanism ADAM17 inhibitors [+2]   | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication-  | 
Drug Highest PhasePreclinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Target  | 
Mechanism CD16a modulators [+2]   | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication-  | 
Drug Highest PhasePreclinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
cam1615TEM8  (  CD16a x IL15R x TEM8 ) | Solid tumor More  | Preclinical  | 
TriKE-PACC(University of Minnesota Twin-Cities)  (  ADAM17 x CD276 x IL-15Rα ) | Solid tumor More  | Preclinical  | 





